Cencora, Inc. (COR) EBITDA Margin: 1.16%
Is Cencora, Inc.’s EBITDA margin high or low?
Cencora, Inc.'s EBITDA margin of 1.16% is 85% above its 5-year average of 0.63%, near the high end of its 5-year range (-2.49%–1.36%).
As of Saturday, June 13, 2026. 0.87% above its 12-month average of 1.15%.
COR EBITDA Margin Chart
COR Average EBITDA Margin Chart
COR Current vs Average EBITDA Margin Chart
COR EBITDA Margin Metrics
EBITDA MARGIN
1.16%
EBITDA MARGIN AVG TTM
1.15%
EBITDA MARGIN AVG 3Y
1.23%
EBITDA MARGIN AVG 5Y
0.63%
EBITDA MARGIN AVG 10Y
0.78%
EBITDA MARGIN AVG 15Y
0.97%
EBITDA MARGIN AVG 20Y
1.05%
CURRENT VS TTM AVG
+0.87%
CURRENT VS 3Y AVG
-5.31%
CURRENT VS 5Y AVG
+84.62%
CURRENT VS 10Y AVG
+49.41%
CURRENT VS 15Y AVG
+19.74%
CURRENT VS 20Y AVG
+10.03%
COR Competitors' EBITDA Margin
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cencora, Inc. (COR) | $54.80B | 1.16% | 1.15% | 1.23% | 0.63% |
| Becton, Dickinson and Company (BDX) | $52.98B | 22.70% | 23.29% | 23.17% | 22.44% |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.06B | 40.57% | 39.01% | 39.25% | 44.24% |
| Humana Inc. (HUM) | $45.53B | 2.24% | 2.50% | 3.66% | 4.53% |
| IDEXX Laboratories, Inc. (IDXX) | $44.24B | 34.13% | 33.43% | 32.56% | 31.99% |
| Agilent Technologies, Inc. (A) | $36.67B | 26.41% | 27.60% | 26.98% | 26.47% |
| Zoetis Inc. (ZTS) | $33.36B | 42.98% | 42.41% | 42.38% | 41.76% |
| Centene Corporation (CNC) | $32.19B | -2.64% | 0.58% | 1.90% | 2.49% |
| Medline Inc. (MDLN) | $30.96B | 6.87% | 10.36% | 10.13% | 10.13% |
| Cigna Corporation (CI) | $78.83B | 4.22% | 4.42% | 5.04% | 5.39% |
Margin Comparison
Gross Margin
3.5%
EBITDA Margin
1.2%
Operating Margin
1.3%
Net Margin
0.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
- Removes effects of depreciation policies (D&A)
- Capital structure neutral (ignores interest)
- Tax neutral (ignores tax differences)
- Good proxy for operating cash generation
Cencora, Inc. EBITDA Margin Formula & Definition
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Cencora, Inc. EBITDA Margin FAQ
- What is the EBITDA margin for Cencora, Inc. (COR)?
- The EBITDA margin for COR stock is 1.16%.
- Is Cencora, Inc.'s EBITDA margin high or low?
- Cencora, Inc.'s EBITDA margin of 1.16% is 85% above its 5-year average of 0.63%, near the high end of its 5-year range (-2.49%–1.36%).
- What is the TTM average EBITDA margin for Cencora, Inc. (COR)?
- The TTM average EBITDA margin for COR stock is 1.15%.
- What is the 3Y average EBITDA margin for Cencora, Inc. (COR)?
- The 3Y average EBITDA margin for COR stock is 1.23%.
- What is the 5Y average EBITDA margin for Cencora, Inc. (COR)?
- The 5Y average EBITDA margin for COR stock is 0.63%.
- What is the 10Y average EBITDA margin for Cencora, Inc. (COR)?
- The 10Y average EBITDA margin for COR stock is 0.78%.
- What is the 15Y average EBITDA margin for Cencora, Inc. (COR)?
- The 15Y average EBITDA margin for COR stock is 0.97%.
- What is the 20Y average EBITDA margin for Cencora, Inc. (COR)?
- The 20Y average EBITDA margin for COR stock is 1.05%.
Cencora, Inc. EBITDA Margin History
| DATE | EBITDA MARGIN |
|---|---|
| 2025-09-30 | 1.16% |
| 2024-09-30 | 1.14% |
| 2023-09-30 | 1.30% |
| 2022-09-30 | 1.30% |
| 2021-09-30 | 1.36% |
| 2020-09-30 | -2.49% |
| 2019-09-30 | 0.92% |
| 2018-09-30 | 1.11% |
| 2017-09-30 | 0.97% |
| 2016-09-30 | 1.31% |
| 2015-09-30 | 0.46% |
| 2014-09-30 | 0.79% |
| 2013-09-30 | 1.21% |
| 2012-09-30 | 1.76% |
| 2011-09-30 | 1.66% |
| 2010-09-30 | 1.54% |
| 2009-09-30 | 1.36% |
| 2008-09-30 | 1.32% |
| 2007-09-30 | 1.45% |
| 2006-09-30 | 1.38% |
| 2005-09-30 | 1.13% |
| 2004-09-30 | 1.83% |
| 2003-09-30 | 1.95% |
| 2002-09-30 | 1.84% |
| 2001-09-30 | 1.90% |
| 2000-09-30 | 1.86% |
| 1999-09-30 | 2.13% |
| 1998-09-30 | 2.25% |
| 1997-09-30 | 1.71% |
| 1996-09-30 | 1.97% |
Related Metrics
About Cencora, Inc.
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Robert Mauch